Is Glaukos Corp (GKOS) a risky stock?
As of July 30, 2026, Clavix grades Glaukos Corp (GKOS) A- for risk, a composite score of 81 out of 100 on an A+ to F scale, which puts GKOS in the "low risk" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 30, 2026. Clavix regrades every trading day.
The five risk dimensions behind GKOS's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how GKOS scores on each, as of July 30, 2026.
What's moving GKOS's risk right now
Company-specific signals Clavix flags behind GKOS's current grade, drawn from recent news and filings as of July 30, 2026.
The substantial upward revision to full-year guidance signals stronger-than-expected demand or execution, likely boosting investor confidence and potentially driving near-term ups…
The strong double-digit revenue growth suggests robust commercial trend in Glaukos's core ophthalmic franchises, which could support continued multiple expansion and upward con…
Intuitive Surgical's valuation has eased as U.S. procedure growth slows, but margin gains, AI software expansion and global growth could support its premium.
Recent GKOS news
The latest headlines Clavix ingested for Glaukos Corp, newest first. These feed the news-sentiment dimension of GKOS's grade.
-
Glaukos reported record Q2 2026 net sales of $185.6 million and raised its full-year 2026 revenue guidance to $680-$700 million from a prior range of $620-$635 million.
-
Glaukos Corporation (NYSE: GKOS) reported record Q2 2026 net sales of $185.6 million, representing 50% year-over-year growth on a reported basis and 49% on a constant currency basis, with the body of the release truncated mid-sentence regarding its glaucoma segment.
What a A- grade means
On the Clavix A+ to F scale, GKOS's composite of 81 falls in the A band (80–100), read as "low risk." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell GKOS or any security. Grades are risk indicators, not predictions of return. Data may be delayed.